{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CDK2", "Hsp90", "VEGFR-2", "cyclin D1", "kinase activity profiling", "luminal-A breast cancer"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "33050377", "DateCompleted": {"Year": "2021", "Month": "05", "Day": "17"}, "DateRevised": {"Year": "2021", "Month": "05", "Day": "17"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "10", "Day": "10"}], "Language": ["eng"], "ELocationID": ["4606", "10.3390/molecules25204606"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "25", "Issue": "20", "PubDate": {"Year": "2020", "Month": "Oct", "Day": "10"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.", "Abstract": {"AbstractText": ["The hormonal luminal-A is the most pre-dominant sub type of breast cancer (BC), and it is associated with a high level of cyclin D1 in Saudi patients. Tamoxifen is the golden therapy for hormonal BC, but resistance of cancer cells to tamoxifen contributes to the recurrence of BC due to many reasons, including high levels of AIB1 and cyclin D1. Overcoming drug resistance could be achieved by exploring alternative targetable therapeutic pathways and new drugs or combinations. The objective of this study was to determine the differentially enriched pathways in 12 samples of Saudi women diagnosed with luminal-A using the PamChip peptide microarray-based kinase activity profiling, and to compare the activity of HAA<sub>2020</sub> and dinaciclib with tamoxifen in singles and combinations in the MCF7 luminal-A cell line. Our results of network and pathway analysis of the 12 samples highlighted the importance of VEGFR and CDKs in promoting luminal-A breast cancer. The activation of VEGF signaling via VEGFR-2 leads to activation of PI3K/AKT kinases and an increase of cell survival, and leads to activation of Hsp90, which induces the phosphorylation of FAK1, resulting in cytoskeleton remodeling. PLC-gamma 1 is also activated, leading to FAK-2 and PKC activation. Notably, the G<sub>1</sub>/S cell cycle phases and phosphorylation processes contribute to the top seven tumorigenesis processes in the 12 samples. Further, the MTT combination of HAA<sub>2020</sub> and dinaciclib showed the best combination index (CI), was more clonogenic against MCF7 cells compared to the other combinations, and it also showed the best selectivity index (SI) in normal MRC5 cells. Interestingly, HAA<sub>2020</sub> and dinaciclib showed a synergistic apoptotic and G<sub>1</sub> cell cycle effect in MCF7 cells, which was supported by their synergistic CDK2, cyclin D1, and PCNA inhibition activities. Additionally, the combination showed VEGFR-2 and Hsp90 inhibition activities in MCF7 cells. The results show the significance of targeting VEGFR-2 and cyclin D1 in Saudi luminal-A breast cancer patients, and the effect of combining HAA<sub>2020</sub> and dinaciclib on those targets in the MCF7 model. It also warrants further preclinical and in vivo investigations for the combination of HAA<sub>2020</sub> and dinaciclib as a possible future second-line treatment for luminal-A breast cancers."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2424, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Breast Cancer Research, Department of Molecular Oncology, King Faisal Specialist Hospital and Research centre, Riyadh, 11211, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences (SMHS), George Washington University, Washington, DC 20073, USA."}], "LastName": "Qattan", "ForeName": "Amal", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Malki", "ForeName": "Waleed H", "Initials": "WH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Shahid", "ForeName": "Imran", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Hossain", "ForeName": "Mohammad Akbar", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Ahmed", "ForeName": "Muhammad", "Initials": "M"}], "GrantList": [{"GrantID": "13-MED873-10", "Agency": "King Abdulaziz City for Science and Technology", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cyclic N-Oxides"}, {"RegistryNumber": "0", "NameOfSubstance": "HSP90 Heat-Shock Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Indolizines"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridinium Compounds"}, {"RegistryNumber": "136601-57-5", "NameOfSubstance": "Cyclin D1"}, {"RegistryNumber": "4V8ECV0NBQ", "NameOfSubstance": "dinaciclib"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "Focal Adhesion Kinase 1"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "Focal Adhesion Kinase 2"}, {"RegistryNumber": "EC 2.7.10.2", "NameOfSubstance": "PTK2B protein, human"}, {"RegistryNumber": "EC 2.7.11.22", "NameOfSubstance": "Cyclin-Dependent Kinase 2"}, {"RegistryNumber": "EC 3.1.4.3", "NameOfSubstance": "Phospholipase C gamma"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["metabolism"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": ["drug effects", "genetics"], "DescriptorName": "Cell Cycle"}, {"QualifierName": [], "DescriptorName": "Cell Line"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Cyclic N-Oxides"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cyclin D1"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Cyclin-Dependent Kinase 2"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Focal Adhesion Kinase 1"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Focal Adhesion Kinase 2"}, {"QualifierName": ["metabolism"], "DescriptorName": "HSP90 Heat-Shock Proteins"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Indolizines"}, {"QualifierName": [], "DescriptorName": "MCF-7 Cells"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Phospholipase C gamma"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Pyridinium Compounds"}, {"QualifierName": ["metabolism"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}], "CoiStatement": "Supplementary Materials: The following are available online at www.mdpi.com/1420-3049/25/20/4606/s1, Figure S1: Key of pathway analysis symbols, Table S2: Enrichment analysis by GO processes, Excel file S3: Breast phosphorylation by tyrosine kinase (PTK) and serine/threonine kinase (STK) data, Figure S4: Histograms of cell cycle analysis in MCF7 cells, Figure S5: Histograms showing detection of apoptosis in MCF7 cells (24 h)."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bray F., Me J.F., Soerjomataram I., Siegel R., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Al-Shahrani Z., Al-Rawaji A., Al-Madouj A.N., Hayder M.S., Al-Zahrani A., Al-Mutlaq H., Bazarbashi S.M.   National Health Information Center; Riyadh, Saudi Arabia: 2017.  [(accessed on 1 September 2020)]. Cancer Incidence Report Saudi Arabia 2014. Available online:  https://nhic.gov.sa/eServices/Documents/2014.pdf."}, {"Citation": "American Cancer Society . Breast Cancer Facts & Figures 2019\u20132020. American Cancer Society; Atlanta, GA, USA: 2019. pp. 1\u201344."}, {"Citation": "Alnegheimish N.A., Alshatwi R.A., Alhefdhi R.M., Arafah M.M., AlRikabi A.C., Husain S. Molecular subtypes of breast carcinoma in Saudi Arabia. Saudi Med. J. 2016;37:506\u2013512. doi: 10.15537/smj.2016.5.15000.", "ArticleIdList": ["10.15537/smj.2016.5.15000", "PMC4880649", "27146612"]}, {"Citation": "Shawarby M., Al-Tamimi D., Ahmed A. Molecular classification of breast cancer: An overview with emphasis on ethnic variations and future perspectives. Saudi J. Med. Med. Sci. 2013;1:14. doi: 10.4103/1658-631X.112908.", "ArticleIdList": ["10.4103/1658-631X.112908"]}, {"Citation": "Mestres J.A., Imolins A.B., Mart\u00ednez L.C., L\u00f3pez-Mu\u00f1iz J.I.C., Gil E.C., Ferr\u00e9 A.D.J., Berr\u00f3n S.D.B., P\u00e9rez Y.F., Mata J.G., Palomo A.G., et al. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. Clin. Transl. Oncol. 2016;19:149\u2013161. doi: 10.1007/s12094-016-1520-2.", "ArticleIdList": ["10.1007/s12094-016-1520-2", "PMC5239809", "27314861"]}, {"Citation": "Mohamed K.E.H., Elamin A. Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an out-patient clinic at Khartoum Oncology Hospital, Sudan. J. Evaluation Clin. Pr. 2020 doi: 10.1111/jep.13373.", "ArticleIdList": ["10.1111/jep.13373", "32101644"]}, {"Citation": "Shagufta, Ahmad I. Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. Eur. J. Med. Chem. 2018;143:515\u2013531. doi: 10.1016/j.ejmech.2017.11.056.", "ArticleIdList": ["10.1016/j.ejmech.2017.11.056", "29207335"]}, {"Citation": "Ximenez J.P.B., De Andrade J.M., Marques M.P., Coelho E.B., Suarez-Kurtz G., Lanchote V.L. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients. BMC Pharmacol. Toxicol. 2019;20:1\u201310. doi: 10.1186/s40360-019-0358-y.", "ArticleIdList": ["10.1186/s40360-019-0358-y", "PMC6921430", "31852530"]}, {"Citation": "Clemons M., Danson S., Howell A. Tamoxifen (\u2018Nolvadex\u2019): A review. Cancer Treat. Rev. 2002;28:165\u2013180. doi: 10.1016/S0305-7372(02)00036-1.", "ArticleIdList": ["10.1016/S0305-7372(02)00036-1", "12363457"]}, {"Citation": "Chang M. Tamoxifen resistance in breast cancer. Biomol. Ther. 2012;20:256\u2013267. doi: 10.4062/biomolther.2012.20.3.256.", "ArticleIdList": ["10.4062/biomolther.2012.20.3.256", "PMC3794521", "24130921"]}, {"Citation": "Haque M., Desai K.V. Pathways to Endocrine Therapy Resistance in Breast Cancer. Front. Endocrinol. 2019;10:573. doi: 10.3389/fendo.2019.00573.", "ArticleIdList": ["10.3389/fendo.2019.00573", "PMC6712962", "31496995"]}, {"Citation": "Munzone E., Curigliano G., Rocca A., Bonizzi G., Renne G., Goldhirsch A., Nole F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res. 2006;8:R1\u2013R4. doi: 10.1186/bcr1606.", "ArticleIdList": ["10.1186/bcr1606", "PMC1413988", "16417653"]}, {"Citation": "Fan P., Wang J., Santen R.J., Yue W. Long-term Treatment with Tamoxifen Facilitates Translocation of Estrogen Receptor \u03b1 out of the Nucleus and Enhances its Interaction with EGFR in MCF-7 Breast Cancer Cells. Cancer Res. 2007;67:1352\u20131360. doi: 10.1158/0008-5472.CAN-06-1020.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-1020", "17283173"]}, {"Citation": "Garc\u00eda-Campos M.A., Espinal-Enr\u00edquez J., Hern\u00e1ndez-Lemus E. Pathway Analysis: State of the Art. Front. Physiol. 2015;6:383. doi: 10.3389/fphys.2015.00383.", "ArticleIdList": ["10.3389/fphys.2015.00383", "PMC4681784", "26733877"]}, {"Citation": "Vishnubalaji R., Nair V.S., Ouararhni K., Elkord E., Alajez N.M. Integrated Transcriptome and Pathway Analyses Revealed Multiple Activated Pathways in Breast Cancer. Front. Oncol. 2019;9:910. doi: 10.3389/fonc.2019.00910.", "ArticleIdList": ["10.3389/fonc.2019.00910", "PMC6759650", "31620367"]}, {"Citation": "Karim S., Merdad A., Schulten H.-J., Jayapal M., Dallol A., Buhmeida A., Al-Thubaity F., Mirza Z., Gari M.A., Chaudhary A.G., et al. Low expression of leptin and its association with breast cancer: A transcriptomic study. Oncol. Rep. 2016;36:43\u201348. doi: 10.3892/or.2016.4806.", "ArticleIdList": ["10.3892/or.2016.4806", "PMC4899016", "27177292"]}, {"Citation": "Merdad A., Karim S., Schulten H.-J., Jayapal M., Dallol A., Buhmeida A., Al-Thubaity F., A GariI M., Chaudhary A.G., Abuzenadah A., et al. Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of Adiponectin and Fatty Acid Binding Protein4: Is lipid metabolism associated with breast cancer? BMC Genom. 2015;16:S11. doi: 10.1186/1471-2164-16-S1-S11.", "ArticleIdList": ["10.1186/1471-2164-16-S1-S11", "PMC4315151", "25923423"]}, {"Citation": "Hilhorst M.H., Houkes L., Korsten H., Mommersteeg M., Trapman J., Ruijtenbeek R. Cellular and Molecular Biology. Volume 71. American Association for Cancer Research (AACR); Philadelphia, PA, USA: 2011. Abstract 4046: Direct detection of AKT/PKB activity in a Pten knock out mouse model using dynamic peptide microarrays; p. 4046."}, {"Citation": "Chirumamilla C.S., Fazil M.H.U.T., Perez-Novo C., Rangarajan S., De Wijn R., Ramireddy P., Verma N.K., Berghe W.V. Profiling Activity of Cellular Kinases in Migrating T-Cells. Adv. Str. Safety Stu. 2019:99\u2013113. doi: 10.1007/978-1-4939-9036-8_13.", "ArticleIdList": ["10.1007/978-1-4939-9036-8_13", "30610604"]}, {"Citation": "Hilhorst R., Houkes L., Mommersteeg M., Musch J., Berg A.V.D., Ruijtenbeek R. Advanced Structural Safety Studies. Volume 977. Springer Science and Business Media LLC; New York, NY, USA: 2013. Peptide Microarrays for Profiling of Serine/Threonine Kinase Activity of Recombinant Kinases and Lysates of Cells and Tissue Samples; pp. 259\u2013271.", "ArticleIdList": ["23436369"]}, {"Citation": "Alkahtani H.M., Abdalla A.N., Obaidullah A.J., Alanazi M.M., Almehizia A.A., Alanazi M.G., Ahmed A.Y., Alwassil O.I., Darwish H.W., Abdel-Aziz A.A.-M., et al. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Bioorg. Chem. 2020;95:103461. doi: 10.1016/j.bioorg.2019.103461.", "ArticleIdList": ["10.1016/j.bioorg.2019.103461", "31838290"]}, {"Citation": "Abdalla A.N., Abdallah M.E., Aslam A., Bader A., Vassallo A., De Tommasi N., Almalki W.H., Gouda A.M., Mukhtar M.H., El-Readi M.Z., et al. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors. Molecules. 2020;25:2220. doi: 10.3390/molecules25092220.", "ArticleIdList": ["10.3390/molecules25092220", "PMC7248782", "32397330"]}, {"Citation": "Comunanza V., Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front. Cell Dev. Biol. 2017;5:101. doi: 10.3389/fcell.2017.00101.", "ArticleIdList": ["10.3389/fcell.2017.00101", "PMC5725406", "29270405"]}, {"Citation": "Barnabas O., Wang H., Gao X.-M. Role of estrogen in angiogenesis in cardiovascular diseases. J. Geriatr. Cardiol. 2013;10:377\u2013382.", "ArticleIdList": ["PMC3888921", "24454332"]}, {"Citation": "Zhao R., Leung E., Gruner S., Schapira M., Houry W.A. Tamoxifen Enhances the Hsp90 Molecular Chaperone ATPase Activity. PLoS ONE. 2010;5:e9934. doi: 10.1371/journal.pone.0009934.", "ArticleIdList": ["10.1371/journal.pone.0009934", "PMC2848575", "20376192"]}, {"Citation": "Zagouri F., Bournakis E., Koutsoukos K., Papadimitriou M. Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer. Pharmaceuticals. 2012;5:1008\u20131020. doi: 10.3390/ph5091008.", "ArticleIdList": ["10.3390/ph5091008", "PMC3816649", "24280702"]}, {"Citation": "Yamaki H., Nakajima M., Shimotohno K.W., Tanaka N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. J. Antibiot. 2011;64:635\u2013644. doi: 10.1038/ja.2011.60.", "ArticleIdList": ["10.1038/ja.2011.60", "21811259"]}, {"Citation": "Prince T., Sun L., Matts R.L. Cdk2: A Genuine Protein Kinase Client of Hsp90 and Cdc37. Biochemistry. 2005;44:15287\u201315295. doi: 10.1021/bi051423m.", "ArticleIdList": ["10.1021/bi051423m", "16285732"]}, {"Citation": "Zagouri F., Sergentanis T.N., Chrysikos D., Papadimitriou M., Dimopoulos M.-A., Psaltopoulou T. Hsp90 inhibitors in breast cancer: A systematic review. Breast. 2013;22:569\u2013578. doi: 10.1016/j.breast.2013.06.003.", "ArticleIdList": ["10.1016/j.breast.2013.06.003", "23870456"]}, {"Citation": "Wang H., Lu M., Yao M., Zhu W. Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials. Mol. Clin. Oncol. 2016;5:326\u2013334. doi: 10.3892/mco.2016.963.", "ArticleIdList": ["10.3892/mco.2016.963", "PMC4998149", "27602225"]}, {"Citation": "Bedin M., Gaben A.-M., Mester J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int. J. Cancer. 2004;109:643\u2013652. doi: 10.1002/ijc.20010.", "ArticleIdList": ["10.1002/ijc.20010", "14999769"]}, {"Citation": "Shuai Z., El-Deiry W.S. Dual Inhibition of Cdk and Hsp90 Destabilize Hif1alpha and Synergistically Induces Cancer Cell Death.  [(accessed on 1 September 2020)];2018  Available online:  https://uspto.report/patent/app/20180243306."}, {"Citation": "Jin H., Dan H.-G., Rao G.-W. Research progress in quinazoline derivatives as multi-target tyrosine kinase inhibitors. Heterocycl. Commun. 2018;24:1\u201310. doi: 10.1515/hc-2017-0066.", "ArticleIdList": ["10.1515/hc-2017-0066"]}, {"Citation": "Park H., Kim Y.-J., Hahn J.-S. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening. Bioorganic Med. Chem. Lett. 2007;17:6345\u20136349. doi: 10.1016/j.bmcl.2007.08.069.", "ArticleIdList": ["10.1016/j.bmcl.2007.08.069", "17869098"]}, {"Citation": "Abdalla A.N., Abdallah M.E., Idris O.F., Alkahtani H.M., Abdel-Aziz A.-M., El-Azab A.S. Mechanistic and Combination Studies of a Novel Dual Her2/EGFR Inhibitor in Breast Cancer Cells; Proceedings of 17th Annual Congress of International Drug Discovery Science and Technology-2019; Kyoto, Japan. 25\u201327 July 2019."}, {"Citation": "Nemenqani D.M. Expression of cyclin D1 in breast carcinoma and its relation to other prognostic markers in Saudi female patients. Int. J. Adv. Res. 2015;3:990\u2013996."}, {"Citation": "Ding L., Cao J., Lin W., Chen H., Xiong X., Ao H., Yu M., Lin J., Cui Q. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int. J. Mol. Sci. 2020;21:1960. doi: 10.3390/ijms21061960.", "ArticleIdList": ["10.3390/ijms21061960", "PMC7139603", "32183020"]}, {"Citation": "Criscitiello C., Viale G., Esposito A., Curigliano G. Dinaciclib for the treatment of breast cancer. Expert Opin. Investig. Drugs. 2014;23:1305\u20131312. doi: 10.1517/13543784.2014.948152.", "ArticleIdList": ["10.1517/13543784.2014.948152", "25107301"]}, {"Citation": "Mita M.M., Joy A.A., Mita A., Sankhala K., Jou Y.-M., Zhang D., Statkevich P., Zhu Y., Yao S.-L., Small K., et al. Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer. Clin. Breast Cancer. 2014;14:169\u2013176. doi: 10.1016/j.clbc.2013.10.016.", "ArticleIdList": ["10.1016/j.clbc.2013.10.016", "24393852"]}, {"Citation": "Chen P., Lee N.V., Hu W., Xu M., Ferre R.A., Lam H., Bergqvist S., Solowiej J., Diehl W., He Y.-A., et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol. Cancer Ther. 2016;15:2273\u20132281. doi: 10.1158/1535-7163.MCT-16-0300.", "ArticleIdList": ["10.1158/1535-7163.MCT-16-0300", "27496135"]}, {"Citation": "Jane E.P., Premkumar D.R., Cavaleri J.M., Sutera P.A., Rajasekar T., Pollack I.F. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines. J. Pharmacol. Exp. Ther. 2015;356:354\u2013365. doi: 10.1124/jpet.115.230052.", "ArticleIdList": ["10.1124/jpet.115.230052", "PMC6047232", "26585571"]}, {"Citation": "Deep G., Agarwal R. New combination therapies with cell-cycle agents. Curr. Opin. Investig. Drugs (Lond. Engl. 2000) 2008;9:591\u2013604.", "ArticleIdList": ["PMC2440501", "18516759"]}, {"Citation": "Dhanjaland P., Fry J.R. Determinants of MTT reduction in rat hepatocytes. Biomarkers. 1997;2:111\u2013116. doi: 10.1080/135475097231832.", "ArticleIdList": ["10.1080/135475097231832", "23889067"]}, {"Citation": "Bruggisser R., Von Daeniken K., Jundt G., Schaffner W., Tullberg-Reinert H. Interference of Plant Extracts, Phytoestrogens and Antioxidants with the MTT Tetrazolium Assay. Planta Medica. 2002;68:445\u2013448. doi: 10.1055/s-2002-32073.", "ArticleIdList": ["10.1055/s-2002-32073", "12058323"]}, {"Citation": "Ostrikov K., Cheng H., Bai Z., Li J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J. Cancer. 2017;8:3131\u20133141. doi: 10.7150/jca.18457.", "ArticleIdList": ["10.7150/jca.18457", "PMC5665029", "29158785"]}, {"Citation": "Com\u015fa \u015e., Cimpean A.M., Raica M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Res. 2015;35:3147\u20133154.", "ArticleIdList": ["26026074"]}, {"Citation": "Subik K., Lee J.-F., Baxter L., Strzepek T., Costello D., Crowley P., Xing L., Hung M.-C., Bonfiglio T., Hicks D.G., et al. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer Basic Clin. Res. 2010;4:35\u201341. doi: 10.1177/117822341000400004.", "ArticleIdList": ["10.1177/117822341000400004", "PMC2914277", "20697531"]}, {"Citation": "Sharma P., Alsharif S., Bursch K., Parvathaneni S., Anastasakis D.G., Chahine J., Fallatah A., Nicolas K., Sharma S., Hafner M., et al. Keratin 19 regulates cell cycle pathway and sensitivity of breast cancer cells to CDK inhibitors. Sci. Rep. 2019;9:1\u201312. doi: 10.1038/s41598-019-51195-9.", "ArticleIdList": ["10.1038/s41598-019-51195-9", "PMC6787034", "31601969"]}, {"Citation": "Crouch B.T., Murphy H., Belonwu S., Martinez A.F., Gallagher J., Hall A., Soo M.S., Lee M., Hughes P., Haystead T., et al. Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens. Sci. Rep. 2017;7:17487. doi: 10.1038/s41598-017-17832-x.", "ArticleIdList": ["10.1038/s41598-017-17832-x", "PMC5727497", "29235516"]}, {"Citation": "Shawky A.M., Abourehab M.A., Abdalla A.N., Gouda A.M. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. Eur. J. Med. Chem. 2020;185:111780. doi: 10.1016/j.ejmech.2019.111780.", "ArticleIdList": ["10.1016/j.ejmech.2019.111780", "31655429"]}, {"Citation": "Makeen H.A., Alhazmi H.A., Khalid A., Al Bratty M., Syame S.M., Abdalla A.N., Homeida H.E., Sultana S., Ahsan W. Phytochemical, antimicrobial and cytotoxicity screening of ethanol extract of Acacia ehrenbergiana Hayne grown in Jazan Region of Saudi Arabia. Trop. J. Pharm. Res. 2020;19:313\u2013321. doi: 10.4314/tjpr.v19i2.14.", "ArticleIdList": ["10.4314/tjpr.v19i2.14"]}, {"Citation": "Attalah K.M., Abdalla A.N., Aslam A., Ahmed M., Abourehab M.A., ElSawy N.A., Gouda A.M. Ethyl benzoate bearing pyrrolizine/indolizine moieties: Design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities. Bioorg. Chem. 2020;94:103371. doi: 10.1016/j.bioorg.2019.103371.", "ArticleIdList": ["10.1016/j.bioorg.2019.103371", "31708230"]}, {"Citation": "Hanahan D., Weinberg R.A. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Abdalla A.N., Shaheen U., Abdallah Q.M.A., Flamini G., Bkhaitan M.M., Abdelhady M.I.S., Ascrizzi R., Bader A. Proapoptotic Activity of Achillea membranacea Essential Oil and Its Major Constituent 1,8-Cineole against A2780 Ovarian Cancer Cells. Molecules. 2020;25:1582. doi: 10.3390/molecules25071582.", "ArticleIdList": ["10.3390/molecules25071582", "PMC7180961", "32235558"]}, {"Citation": "Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim. Biophys. Acta (BBA)-Bioenerg. 2010;1806:108\u2013121. doi: 10.1016/j.bbcan.2010.04.004.", "ArticleIdList": ["10.1016/j.bbcan.2010.04.004", "PMC2885515", "20462514"]}, {"Citation": "Zhang Q., Lu S., Li T., Yu L., Zhang Y., Zeng H., Qian X., Bi J., Lin Y. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J. Exp Clin Cancer Res. 2019;38:1\u201312. doi: 10.1186/s13046-019-1156-5.", "ArticleIdList": ["10.1186/s13046-019-1156-5", "PMC6482513", "31023337"]}, {"Citation": "Ceci C., Atzori M.G., Lacal P.M., Graziani G. Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models. Int. J. Mol. Sci. 2020;21:1388. doi: 10.3390/ijms21041388.", "ArticleIdList": ["10.3390/ijms21041388", "PMC7073125", "32085654"]}, {"Citation": "Wu Y., Rafii S., Witte L. Vegfr-1 Antibodies to Treat Breast Cancer. 2004/0241160 A1. U.S. Patent. 2004 Dec 2;"}, {"Citation": "Abdallah M.E., El-Readi M.Z., Althubiti M.A., Almaimani R.A., Ismail A.M., Idris S., Refaat B., Almalki W.H., Babakr A.T., Mukhtar M.H., et al. Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells. Molecules. 2020;25:3355. doi: 10.3390/molecules25153355.", "ArticleIdList": ["10.3390/molecules25153355", "PMC7436112", "32722075"]}]}], "History": [{"Year": "2020", "Month": "9", "Day": "8"}, {"Year": "2020", "Month": "9", "Day": "29"}, {"Year": "2020", "Month": "10", "Day": "6"}, {"Year": "2020", "Month": "10", "Day": "14", "Hour": "1", "Minute": "4"}, {"Year": "2020", "Month": "10", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "10", "Day": "10"}], "PublicationStatus": "epublish", "ArticleIdList": ["33050377", "PMC7594023", "10.3390/molecules25204606", "molecules25204606"]}}]}